News

January 25, 2021January 25, 2021

Retifanlimab Under FDA Priority Review for Advanced Anal Canal Cancer

News

Retifanlimab is under review in the U.S. as a treatment for advanced squamous cell carcinoma of the anal canal (SCAC), a rare cancer of the digestive system, in adults ... Read more

January 22, 2021January 22, 2021

FDA Agrees to Priority Review of Opdivo for Gastric, Esophageal Cancers

News

The U.S. Food and Drug Administration (FDA) has accepted for review — under priority status — two applications requesting the approval of Opdivo (nivolumab) for treating several types of ... Read more

January 20, 2021January 20, 2021

Tecentriq-Avastin Combo Leads to ‘Longest Survival’ in Liver Cancer

News

First-line therapy with a combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) significantly prolongs the survival of people with inoperable hepatocellular carcinoma (HCC) — the most common form of liver ... Read more

January 18, 2021January 18, 2021

Less-frequent Dosing of Imfinzi Approved in Europe for Advanced Lung Cancer

News

A less-frequent, fixed dose regimen of Imfinzi (durvalumab) has been approved in the European Union and U.K. to treat adults with locally advanced, inoperable non-small cell lung cancer (NSCLC), ... Read more

January 15, 2021January 15, 2021

T-cell Therapy Showing Promise in Synovial Sarcoma Patients in Phase 1 Trial

News

ADP-A2M4, an investigational therapy that uses engineered immune cells to fight cancer, showed an acceptable safety profile and promising effectiveness in people with synovial sarcoma, a rare cancer that ... Read more

January 11, 2021January 11, 2021

Personalized AV-GBM-1 Vaccine Shows Promise for Aggressive Brain Cancer

News

Adding AIVITA Biomedical’s experimental and personalized cancer vaccine, AV-GBM-1, to post-surgery standard treatment slows disease progression in adults newly diagnosed with glioblastoma — the most aggressive type of brain ... Read more

January 8, 2021January 8, 2021

Cavrotolimod Plus PD-1 Blockers Showing Efficacy in Advanced Cancers, Trial Reports

News

The investigational therapy cavrotolimod (AST-008), in combination with the PD-1 inhibitor Keytruda (pembrolizumab), was safe and well-tolerated, and showed signs of efficacy in people with advanced solid tumors who ... Read more

January 6, 2021January 6, 2021

Tiragolumab-Tecentriq Combo for NSCLC Earns Breakthrough Therapy Status

News

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to a combination of tiragolumab, a novel immunotherapy developed by Genentech, plus Tecentriq (atezolizumab) for ... Read more

January 4, 2021January 8, 2021

Triple Combo With Libtayo Shows Promise in Hard-to-treat Brain Cancer

News

Combining two experimental cancer vaccines with Libtayo (cemiplimab) promotes strong anti-tumor immune responses and shows early signs of effectiveness in adults newly diagnosed with glioblastoma — the most aggressive ... Read more

December 21, 2020December 21, 2020

Cancer Vaccines Get FDA Breakthrough Status in Advanced Melanoma Combo Therapy

News

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to a combination treatment of IO Biotech’s lead anti-cancer vaccine candidates IO102 and IO103, plus ... Read more